These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26243033)

  • 1. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
    Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
    Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
    Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
    Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
    Muhammad A; van der Lely AJ; O'Connor RD; Delhanty PJ; Dal J; Dallenga AH; Feelders RA; Janssen JA; Jorgensen JO; Neggers SJ
    Eur J Endocrinol; 2016 May; 174(5):663-7. PubMed ID: 26903550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
    Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
    Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
    Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.
    Franck SE; Korevaar TIM; Petrossians P; Daly AF; Chanson P; Jaffrain-Réa ML; Brue T; Stalla GK; Carvalho D; Colao A; Hána V; Delemer B; Fajardo C; van der Lely AJ; Beckers A; Neggers SJCMM
    Eur J Endocrinol; 2017 Apr; 176(4):421-431. PubMed ID: 28100630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
    Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
    J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.
    Filopanti M; Olgiati L; Mantovani G; Corbetta S; Arosio M; Gasco V; De Marinis L; Martini C; Bogazzi F; Cannavò S; Colao A; Ferone D; Arnaldi G; Pigliaru F; Peri A; Angeletti G; Jaffrain-Rea ML; Lania AG; Spada A
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E165-72. PubMed ID: 22162472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients.
    de Oliveira Machado E; Lima CH; Ogino LL; Kasuki L; Gadelha MR
    Pituitary; 2016 Aug; 19(4):375-80. PubMed ID: 27001494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly.
    Kamenicky P; Dos Santos C; Espinosa C; Salenave S; Galland F; Le Bouc Y; Maison P; Bougnères P; Chanson P
    Eur J Endocrinol; 2009 Aug; 161(2):231-5. PubMed ID: 19439509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothesis: Extra-hepatic acromegaly: a new paradigm?
    Neggers SJ; Kopchick JJ; Jørgensen JO; van der Lely AJ
    Eur J Endocrinol; 2011 Jan; 164(1):11-6. PubMed ID: 21045065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
    Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
    Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegvisomant in acromegaly: a multicenter real-life study in Argentina.
    Basavilbaso NXG; Ballarino MC; Bruera D; Bruno OD; Chervin AB; Danilowicz K; Fainstein-Day P; Fidalgo SG; Frigeri A; Glerean M; Guelman R; Isaac G; Katz DA; Knoblovits P; Librandi F; Montes ML; Mallea-Gil MS; Manavela M; Mereshian P; Moncet D; Pignatta A; Rogozinsky A; Sago LR; Servidio M; Spezzi M; Stalldecker G; Tkatch J; Vitale NM; Guitelman M
    Arch Endocrinol Metab; 2019 Aug; 63(4):320-327. PubMed ID: 31460622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brazilian multicenter study on pegvisomant treatment in acromegaly.
    Boguszewski CL; Huayllas MKP; Vilar L; Naves LA; Ribeiro-Oliveira Junior A; Soares BS; Czepielewski MA; Abucham J; Correa-Silva SR; Bronstein MD; Jallad RS; Duarte FG; Musolino NR; Kasuki L; Gadelha MR
    Arch Endocrinol Metab; 2019 Jul; 63(4):328-336. PubMed ID: 31365632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
    Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
    Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
    Bianchi A; Valentini F; Iuorio R; Poggi M; Baldelli R; Passeri M; Giampietro A; Tartaglione L; Chiloiro S; Appetecchia M; Gargiulo P; Fabbri A; Toscano V; Pontecorvi A; De Marinis L
    J Exp Clin Cancer Res; 2013 Jun; 32(1):40. PubMed ID: 23799893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
    Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful use of weekly pegvisomant administration in patients with acromegaly.
    Higham CE; Thomas JD; Bidlingmaier M; Drake WM; Trainer PJ
    Eur J Endocrinol; 2009 Jul; 161(1):21-5. PubMed ID: 19411301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.